➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Merck
McKinsey
Mallinckrodt
Harvard Business School

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Cefepime And Dextrose In Duplex Container patents expire, and what generic alternatives are available?

Cefepime And Dextrose In Duplex Container is a drug marketed by B Braun and is included in one NDA.

The generic ingredient in CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER is cefepime hydrochloride. There are twenty drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the cefepime hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Cefepime And Dextrose In Duplex Container

A generic version of CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER was approved as cefepime hydrochloride by ACS DOBFAR on March 20th, 2008.

  Start Trial

Summary for CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER
Drug patent expirations by year for CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER
Pharmacology for CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

US Patents and Regulatory Information for CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
B Braun CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER cefepime hydrochloride INJECTABLE;INJECTION 050821-001 May 6, 2010 RX No No   Start Trial   Start Trial   Start Trial
B Braun CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER cefepime hydrochloride INJECTABLE;INJECTION 050821-002 May 6, 2010 RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
AstraZeneca
Moodys
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.